For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
LL-37 is the only cathelicidin produced by the human genome, derived from the precursor protein hCAP18. It is a front-line innate immune peptide deficient in chronic wounds (venous leg ulcers, diabetic foot ulcers) but present in normal acute wounds. Two Phase 2 RCTs (n=34 and n=144) established topical LL-37 as safe and wound-healing efficacious, with the clearest benefit in large ulcers (10 cm2 or larger). No Phase 3 data exist. Published preclinical evidence documents pro-tumorigenic activity in ovarian, lung, breast, prostate, and melanoma contexts, and a role as a T-cell autoantigen in psoriasis and SLE, constituting mandatory safety disclosures for any research context.
LL-37 sits at the intersection of three distinct research conversations requiring careful separation: therapeutic wound healing, its endogenous role as a driver of autoimmune disease pathogenesis, and its dual and contested role in cancer biology. The biohacker community focuses on the first. The published literature demands equal attention to the second and third.
The wound healing evidence is genuinely promising and human-validated. Two Phase 2 trials (Phase IIa: n=34; Phase IIb: n=144) conducted by Promore Pharma (Sweden) established topical LL-37 (Ropocamptide) as safe and efficacious for accelerating healing of hard-to-heal venous leg ulcers. The critical limitation: the Phase IIb primary endpoint was not statistically significant in the overall population. Benefit was confined to the pre-specified subgroup with large wounds (10 cm2 or larger). No Phase 3 trial has been completed. No regulatory approval exists anywhere.
The cancer biology data is a mandatory disclosure. Published peer-reviewed evidence across multiple independent research groups demonstrates that LL-37 promotes tumor growth in ovarian, lung, breast, prostate, pancreatic, melanoma, liver, and skin squamous cell carcinoma models. In contrast, it inhibits cancer in colon, gastric, hematologic, glioblastoma, and oral squamous cell carcinoma contexts. The pro-tumorigenic mechanisms operate through receptor tyrosine kinase and G protein-coupled receptor activation. No clinical trials have assessed cancer risk from exogenous LL-37; the wound healing trials were too short and too narrow in patient selection to detect a tumor-promoting signal.
Endogenous LL-37 also functions as a documented T-cell autoantigen in psoriasis (two-thirds of patients carry reactive T cells) and as a driver of pathogenic autoantibody production in systemic lupus erythematosus. Exogenous administration in autoimmune-predisposed individuals is theoretically capable of amplifying these pathways, though no clinical evidence of this has been reported in wound healing trials.
LL-37 is the C-terminal 37-amino acid peptide cleaved from its precursor hCAP18 (human cationic antimicrobial protein 18) by the serine protease proteinase 3. It is the only cathelicidin encoded by the human genome. The name reflects its leucine-leucine N-terminal sequence and its 37-amino acid length.
First characterized in the mid-1990s from human neutrophil granules, LL-37 has since been identified in epithelial cells of the skin, gastrointestinal tract, and respiratory mucosa; in monocytes, T cells, NK cells, and B cells; and in secretions including sweat, saliva, breast milk, and seminal plasma. It is a front-line component of innate immunity present from birth.
Its central structural feature is an amphipathic alpha-helix covering residues 2 to 31, which allows the positively charged face to engage anionic bacterial membranes while the hydrophobic face inserts into the lipid bilayer, causing disruption and cell death. This mechanism differs from conventional antibiotics, which is why research interest centered initially on activity against multidrug-resistant organisms.
The therapeutic development story is dominated by Promore Pharma in Sweden, which has run the only blinded, placebo-controlled human trials of native LL-37. Their program targets chronic wound healing based on the key observation that venous leg ulcers and diabetic foot ulcers are deficient in endogenous LL-37 despite its abundance in normal acute wounds.
LL-37 operates across four distinct biological axes simultaneously. Understanding which axis dominates in a given context is essential for interpreting both therapeutic potential and risk.
Direct membrane disruption (antimicrobial axis): The amphipathic alpha-helix allows selective insertion into negatively charged bacterial and fungal membranes, causing ion leakage and cell death. This mechanism has been confirmed against more than 38 bacterial species, 16 fungal species, and 16 viral species in vitro. Critically, the concentration required for antimicrobial killing overlaps with concentrations causing hemolysis and cytotoxicity in mammalian cells, precluding systemic therapeutic development. Topical application sidesteps this by achieving local concentrations without systemic exposure.
Wound healing and angiogenesis axis: LL-37 stimulates keratinocyte migration and proliferation via EGFR transactivation. It promotes angiogenesis through VEGF upregulation. It modulates wound inflammation by attracting monocytes and granulocytes via FPR2 (formyl peptide receptor 2) and then facilitating resolution. Venous leg ulcers and diabetic foot ulcers are deficient in endogenous LL-37; the therapeutic hypothesis is that exogenous LL-37 restarts the normal acute wound healing cascade.
Immunomodulation and autoimmunity axis: LL-37 has high affinity for nucleic acids. When complexed with self-DNA or self-RNA released during NETosis, it shuttles these complexes into plasmacytoid dendritic cells, triggering TLR7 and TLR9 signaling and a type I interferon response. In healthy individuals this is a normal innate immune circuit. In genetically susceptible individuals this same mechanism drives psoriasis (LL-37 as Th17 T-cell autoantigen) and SLE (LL-37 driving TFH-mediated anti-DNA autoantibody production).
Cancer axis (context-dependent and dual): LL-37 activates a range of membrane receptors expressed differentially across tumor types: FPR2, EGFR, ErbB2, TRPV2, P2X7, and others. In tumors where these receptors drive proliferation (ovarian, lung, breast, prostate, melanoma), LL-37 activates pro-tumorigenic signaling cascades including PI3K/Akt, Wnt/beta-catenin, and MAPK pathways. In colon cancer and hematologic malignancies, receptor expression patterns differ and LL-37 instead induces apoptosis via BMP signaling modulation. No unified mechanistic explanation for this tissue specificity has been established as of 2026.
Phase IIa (Gronberg 2014, n=34): Healing rate constants at 0.5 mg/mL and 1.6 mg/mL were approximately six-fold and three-fold higher than placebo respectively. The 0.5 mg/mL result reached statistical significance (p=0.003). Square-root transformed wound area showed improved healing versus pretreatment for both lower doses (p less than 0.001 and p=0.011). The 3.2 mg/mL dose showed no additional benefit. No serious adverse events attributable to the investigational product occurred.
Phase IIb (Mahlapuu HEAL LL-37, n=144): The primary endpoint, wound area reduction in the overall population, did not reach statistical significance. In the pre-specified subgroup of patients with large ulcers (10 cm2 or larger), ropocamptide showed a statistically significant improvement versus placebo. Over three months, more than three times as many patients in the ropocamptide group achieved complete wound healing compared to standard compression therapy alone. The 0.5 mg/mL dose again outperformed 1.6 mg/mL, confirming the Phase IIa dose-response pattern. Safety was acceptable across both doses at 15 sites.
The most clinically validated application of LL-37. Two Phase 2 RCTs establish dose-response consistency, acceptable safety, and a real wound healing signal. The Phase IIb overall-population miss is a genuine negative that must not be minimized. The subgroup finding in large wounds (10 cm2 or larger) drives the Phase 3 planning but has not been independently replicated. This is the strongest evidence base of any AMP in the biohacker canon, and it still has not cleared Phase 3.
LL-37 cream significantly improved granulation index on all four measurement days versus placebo (p=0.031, 0.009, 0.006, and 0.037 on days 7, 14, 21, and 28). Reduction in aerobic bacterial colonization was greater in the LL-37 group on days 7, 14, and 21 but greater in the placebo group on day 28, and none of these differences reached statistical significance.
Primary negative findings: LL-37 did not significantly reduce IL-1alpha or TNF-alpha inflammatory cytokine levels in wound fluid, which had been hypothesized as a secondary mechanism. The inflammation-modulating mechanism proposed for VLUs did not translate to the DFU context in this trial.
An important stability caveat: separate proteolysis research demonstrated that LL-37 is completely degraded overnight by wound fluid from diabetic foot ulcers in vitro, calling into question whether direct peptide activity or secondary host effects explain the granulation benefit.
Encouraging granulation data in the only published RCT of LL-37 in DFU. Significant on the primary granulation measure but negative on cytokine and bacterial endpoints. The protease degradation data from the DFU microenvironment are a meaningful mechanistic concern. DFU pathophysiology differs substantially from VLU and the VLU data should not be taken as predictive. A larger adequately powered trial analogous to HEAL LL-37 is needed before DFU conclusions can be drawn.
Pro-tumorigenic: LL-37 promotes tumor growth in ovarian, lung, breast, prostate, pancreatic, melanoma, liver, and skin squamous cell carcinoma via activation of receptor tyrosine kinases (EGFR, ErbB2), G protein-coupled receptors (FPR2), and ion channels (TRPV2, P2X7). Downstream mechanisms include PI3K/Akt activation, Wnt/beta-catenin signaling, MAPK pathway induction, MMP secretion, and enhanced epithelial-mesenchymal transition. These findings come from multiple independent research groups across different institutions.
Anti-tumorigenic: In colon cancer, gastric cancer, hematologic malignancies, glioblastoma, and oral squamous cell carcinoma, LL-37 suppresses proliferation and induces apoptosis and autophagy via BMP signaling pathway modulation and proteasome activation.
No clinical trials have assessed exogenous LL-37 in any cancer context. No cancer incidence data from wound healing trials have been published. The opposing effects are not explained by a unified mechanism; tissue-specific receptor expression differences are the leading hypothesis.
This is the most important safety disclosure in this profile. The pro-tumorigenic evidence is replicated across multiple independent groups in multiple tumor types. It is preclinical, but it is not a single discordant finding. Individuals with known or suspected ovarian, lung, breast, prostate, or melanoma cancer should regard exogenous LL-37 as contraindicated pending human safety data. The wound healing trials are too short (13 to 17 weeks) and too narrow to have detected a tumor promotion signal.
LL-37 demonstrates MIC activity against more than 38 bacterial species in vitro, including MRSA, Pseudomonas aeruginosa, E. coli, and Klebsiella pneumoniae. It disrupts both biofilm formation and established biofilms at concentrations potentially achievable topically. LL-37 activity has been confirmed against 16 fungal species and 16 viral species.
Critical limitations: MIC values for LL-37 overlap with concentrations causing mammalian cell toxicity and hemolysis, precluding systemic use as a conventional antibiotic. Clinical bacterial isolates from ocular and auricular infections showed substantially higher MIC values than laboratory reference strains, suggesting exposure-driven adaptation challenges the initial claim that membrane-disrupting AMPs do not engender resistance.
A derivative fragment, AMP60.4Ac (OP-145, 24 amino acids), was evaluated in a randomized double-blind placebo-controlled Phase 2 study for chronic suppurative otitis media with results supporting continued development. AMP60.4Ac is not the same compound as native LL-37.
The in vitro antimicrobial data for LL-37 are among the most thoroughly characterized of any AMP. No controlled human trial has demonstrated antimicrobial efficacy of native LL-37 as a standalone antibiotic. The cytotoxicity-efficacy overlap prevents systemic antibiotic use. Analog development is the active area for antimicrobial applications. Anti-biofilm activity in wound models likely contributes to VLU healing results but cannot be cleanly separated from wound-healing mechanisms in clinical trial data.
In psoriasis: approximately two-thirds of patients carry circulating T cells reactive to LL-37. These are primarily Th17-phenotype. The mechanism involves LL-37 complexing with self-DNA released during NETosis, entering plasmacytoid dendritic cells, triggering TLR7/TLR9 signaling, type I interferon production, and initiating a self-directed adaptive immune response. Post-translational modifications of LL-37 (citrullination, carbamylation) alter the T-cell phenotype and may influence disease severity and the psoriasis-to-psoriatic arthritis transition.
In SLE: 45% of patients carry LL-37-reactive T cells with a T-follicular helper phenotype (CXCR5+/Bcl-6+/IL-21+). These promote B-cell secretion of anti-LL-37 autoantibodies that correlate with disease activity. This mechanism is distinct from the psoriasis Th17 pathway.
In rheumatoid arthritis: elevated LL-37 and its activating protease are present in arthritic joints. LL-37 induces osteoblast apoptosis, potentially contributing to periarticular bone loss in RA.
Endogenous LL-37 is not uniformly beneficial. In individuals with psoriasis, SLE, or RA, it actively drives disease pathogenesis via the LL-37/DNA/pDC/type I interferon circuit. Exogenous LL-37 in these patient populations could theoretically amplify established pathogenic T-cell responses. No clinical evidence of this has been reported in wound healing trials, but those trials did not characterize patients for autoimmune status. This is a mechanistically grounded and human-data-supported theoretical risk, not speculation.
Cathelicidin antimicrobial peptide. Immunomodulatory. Limited human injectable data.
All human clinical data are for topical wound application only. Subcutaneous dosing of 100 to 500 mcg circulates in biohacker communities but has no published human PK data, no established therapeutic dose, and does not reflect the route or indication studied in any clinical trial. LL-37 is rapidly degraded by tissue proteases; systemic concentration-time profiles at subcutaneous doses are entirely uncharacterized. The cancer and autoimmune safety signals documented in preclinical and human observational data are unaddressed for the systemic injection route.
Among wound-healing peptides in this series, LL-37 has the most direct human clinical evidence, surpassing BPC-157 (no human trials) and GHK-Cu (human data largely cosmetic, no Phase 2 RCT in wounds). Its safety complexity, simultaneously the most validated wound healer in this series and carrying cancer and autoimmune disclosures absent from simpler peptides, makes it unlike any other profile in this database. KPV has overlapping anti-inflammatory and wound-healing biology but zero human data. TB-500 has tissue repair claims but its human data belong to the parent molecule TB4, not the synthetic fragment. LL-37 is the only AMP in this series with GCP-compliant Phase 2 wound trial data.
In wound healing trials, both Phase 2 studies (n=34 and n=144) reported no serious adverse events attributable to LL-37. Local tolerability at the wound site was acceptable. Inflammation and skin irritation were monitored in Phase IIb and did not differ meaningfully from placebo. This safety record covers topical administration only; systemic injection safety in humans is not established by clinical trial data.
Hemolysis and cytotoxicity: LL-37 is cytotoxic to mammalian cells at concentrations overlapping with its antimicrobial range. In vitro hemolysis is well-documented and is the primary reason it has not been developed as a systemic antibiotic. The selectivity index for native LL-37 is low relative to its analogs. At subcutaneous doses circulated in the biohacker community (100 to 500 mcg), systemic cytotoxicity risk is unknown because no published PK data characterize the concentration-time profile.
Proteolytic instability: LL-37 is completely degraded overnight by wound fluid from diabetic foot ulcers in vitro. This rapid degradation limits both efficacy and systemic exposure from topical routes, which serves as a partial safety mitigant for topical use.
Cancer risk (mandatory disclosure): Pro-tumorigenic activity in ovarian, lung, breast, prostate, melanoma, liver, and skin squamous cell carcinoma has been documented in multiple independent cell culture and animal studies. Whether exogenous LL-37 at wound healing doses promotes tumor growth in humans is unknown. Trial durations of 13 to 17 weeks are too short to detect a tumor promotion signal. Individuals with personal or strong family history of these cancer types should regard exogenous LL-37 as contraindicated pending human safety data.
Autoimmune amplification risk: Individuals with psoriasis, SLE, or rheumatoid arthritis may have pathogenic T-cell responses to LL-37 already established. Exogenous LL-37 could theoretically amplify these via the LL-37/DNA complex and pDC/type I interferon axis. No clinical evidence of this has been reported in wound healing trials, but those trials did not characterize or exclude patients by autoimmune disease status.
LL-37 is the most clinically validated peptide in the antimicrobial and host-defense category covered by The Signal. Two Phase 2 trials with approximately 178 total participants, conducted under GCP with independent ethics committee review, established a genuine wound-healing signal and acceptable topical safety profile. No other AMP in the biohacker conversation has cleared that bar.
The honest picture is more complicated than vendor copy suggests. The Phase IIb primary endpoint was missed. Benefit was confined to a pre-specified subgroup. No Phase 3 data exist. The pro-tumorigenic cancer biology data, replicated independently across multiple research groups in multiple tumor types, constitutes a legitimate safety concern that is not resolved by the short-duration topical wound healing trials. The autoimmune pathogenesis data add a second independent concern for the approximately 7 to 8 percent of the population with active autoimmune disease.
For the research community: LL-37 wound healing potential is real and the most scientifically credible AMP application in human medicine. For individuals self-experimenting with systemic subcutaneous LL-37 based on the wound healing data: the route (topical versus subcutaneous), systemic exposure profile, and cancer biology context are entirely unaddressed by existing human evidence. That gap deserves serious weight before any personal research protocol is designed.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use